History

Advanced Accelerator Applications was founded in 2002 by physicist Stefano Buono, who was inspired to pursue medical applications for certain research conducted during his tenure at the European Organization for Nuclear Research, or CERN, with Nobel laureate Carlo Rubbia.

2002

Advanced Accelerator Applications Founded

2004-2006

First Cyclotron Built in France

2009-2010

EMA approval of Gluscan 500

2009-2010

Obtained the rights to develop and commercialize Lutathera®

2015-2016

Listed on NASDAQ

2015-2016

FDA approval of NETSPOT® and EMA approval of SomaKit TOC®

2018

Acquired by Novartis

2018

FDA approval of Lutathera®

2018

Endocyte acquisition

2019-2021

EMA approval of LysaKare®

2022

Ivrea RLT site line expansion

2022

Saint-Genis Pouilly Molecular Imaging site line expansion

2022

FDA and EMA approval of Pluvicto® and Locametz®

2023

Completion of new RLT site in Indianapolis, US

2023

Start of construction of Molecular Imaging site in Salamanca, Spain

2023

Announced plans to build RLT manufacturing capabilities in Sasayama, Japan and Haiyan, Zhejiang, China

2002

Advanced Accelerator Applications Founded

2004-2006

First Cyclotron Built in France

2009-2010

EMA approval of Gluscan 500

2009-2010

Obtained the rights to develop and commercialize Lutathera®

2015-2016

Listed on NASDAQ

2015-2016

FDA approval of NETSPOT® and EMA approval of SomaKit TOC®

2018

Acquired by Novartis

2018

FDA approval of Lutathera®

2018

Endocyte acquisition

2019-2021

EMA approval of LysaKare®

2022

Ivrea RLT site line expansion

2022

Saint-Genis Pouilly Molecular Imaging site line expansion

2022

FDA and EMA approval of Pluvicto® and Locametz®

2023

Completion of new RLT site in Indianapolis, US

2023

Start of construction of Molecular Imaging site in Salamanca, Spain

2023

Announced plans to build RLT manufacturing capabilities in Sasayama, Japan and Haiyan, Zhejiang, China